• Refining In Vitro Drug Response Metrics in Cancer Research

  2026-07-07

  Schwartz's dissertation introduces a dual-metric approach to evaluating anti-cancer drug responses in vitro, distinguishing proliferative arrest from cell death. This refined methodology enables more precise interpretation of drug effects, with practical implications for preclinical assessment of agents such as kinesin spindle protein inhibitors.

• Evaluating Drug Responses in Cancer: Insights from In Vitro

  2026-07-06

  Schwartz's dissertation advances the evaluation of anti-cancer drugs by distinguishing between proliferative arrest and cell death using refined in vitro metrics. These methodological innovations clarify how agents like histone deacetylase inhibitors affect tumor cell fate, providing a more nuanced framework for preclinical drug assessment.

• ATM Inhibition and Fenofibrate Synergy in Ovarian Cancer Cel

  2026-07-06

  This study demonstrates that targeting ATM kinase in high grade serous ovarian cancer (HGSOC) cells, especially when combined with the metabolic modulator fenofibrate, induces cellular senescence and suppresses tumor cell viability. The findings highlight a novel therapeutic avenue for HR-proficient HGSOC, a patient group poorly served by current DNA repair-targeted therapies.

• Romidepsin (FK228): Epigenetic Reprogramming Beyond HDAC Inh

  2026-07-05

  Explore how Romidepsin (FK228) enables advanced epigenetic modulation as a precise HDAC inhibitor for cancer therapy research. This article reveals unique mechanistic insights and practical assay guidance, bridging new proteomics findings with next-generation experimental design.

• RESTRICT-seq Maps Epigenetic Dependencies in SCC Resistance

  2026-07-04

  The referenced study introduces RESTRICT-seq, a time-gated CRISPR screening platform, to uncover novel epigenetic dependencies underlying squamous cell carcinoma (SCC) resistance. This approach enables precise dissection of chromatin regulator function and reveals new avenues for oncogene-induced senescence induction and therapeutic targeting.

• N1-Methylpseudouridine: Optimizing mRNA Translation Workflow

  2026-07-03

  N1-Methylpseudouridine empowers researchers to achieve superior mRNA translation efficiency and reduced immunogenicity in both in vitro and in vivo models. This guide delivers actionable workflows, troubleshooting tips, and bridges cutting-edge metabolic regulation insights for advanced mRNA applications.

• Gefitinib (ZD1839): Precision EGFR Pathway Inhibition in Adv

  2026-07-03

  Delve into the scientific intricacies of Gefitinib (ZD1839) as a potent EGFR pathway inhibitor. This article uniquely explores its mechanistic depth, experimental optimization, and translational significance, setting it apart from existing overviews.

• Ibotenic Acid in Precision Neurodegeneration Modeling

  2026-07-02

  Explore how Ibotenic acid empowers advanced, lesion-based neurodegenerative disease models through selective NMDA receptor agonism. This in-depth guide reveals new assay strategies and circuit insights, setting it apart from prior content.

• Raising the Bar in OXPHOS Research: Protease Inhibition for

  2026-07-02

  This thought-leadership article explores the critical role of advanced protease inhibitor cocktails—specifically, the EDTA-free, DMSO-based formulation from APExBIO—in safeguarding protein integrity during translational OXPHOS research. By weaving together recent mechanistic breakthroughs in dual-genome OXPHOS disruption and practical experimental strategies, the article provides translational researchers with actionable insights for robust assay development, competitive differentiation, and high-impact discovery.

• Advancing In Vitro Evaluation of Anti-Cancer Drug Responses

  2026-07-01

  Schwartz’s dissertation introduces a more nuanced framework for evaluating anti-cancer drug efficacy in vitro by differentiating between proliferative arrest and cell death. This approach challenges the traditional reliance on aggregated viability metrics, with significant implications for translational oncology and drug development.

• Decoding Golgi Dynamics: Strategic Advances with Golgi-Track

  2026-07-01

  Explore how APExBIO’s Golgi-Tracker Green redefines live-cell Golgi apparatus imaging, bridging mechanistic insight, translational research, and competitive benchmarking. This thought-leadership piece integrates cutting-edge breast cancer findings, scenario-driven laboratory evidence, and strategic guidance for leveraging organelle-targeted probes in next-generation biomedical discovery.

• Cholesterol Impairs Lipid Nanoparticle Trafficking via Endos

  2026-06-30

  This study reveals how elevated cholesterol content in lipid nanoparticles (LNPs) disrupts their intracellular trafficking by promoting aggregation in peripheral early endosomes. The findings clarify a major bottleneck in LNP-mediated nucleic acid delivery and inform future nanoparticle design for improved therapeutic efficacy.

• CD36-Driven Lipid Metabolism Confers Immune Escape in AML

  2026-06-30

  This study uncovers a non-canonical lipid metabolism program in acute myeloid leukemia (AML), orchestrated by CD36, that suppresses T cell immunity and confers resistance to hypomethylating therapy. By dissecting the synergy between exogenous lipids and innate immune signaling, the research reveals actionable metabolic vulnerabilities for translational cancer immunotherapy.

• Chlorpromazine HCl: Advanced Mechanisms in Endocytosis and D

  2026-06-29

  Explore the multifaceted role of Chlorpromazine HCl as a dopamine receptor antagonist and modulator of endocytosis in neuropharmacology research. This article reveals new mechanistic insights and practical protocols, distinguishing itself with a deep dive into cross-talk between receptor inhibition and advanced nanoparticle uptake assays.

• Optimizing Heme Biosynthesis with 5-Aminolevulinic acid HCl

  2026-06-29

  5-Aminolevulinic acid HCl offers precise control over heme biosynthesis and pathogen immune evasion modeling. This guide details advanced workflows, troubleshooting, and translational applications for both cancer and infection biology using APExBIO’s high-purity reagent.

449 records 12/30 page Previous Next First page 上5页 1112131415 下5页 Last page